Literature DB >> 12135309

Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients.

Kazuo Eguchi1, Kazuomi Kario, Kazuyuki Shimada.   

Abstract

We studied differences in the effects of a long-acting angiotensin-converting enzyme (ACE) inhibitor (temocapril) and a long-acting calcium channel blocker (amlodipine) on ventricular ectopic beats (VEB) in relation to sympathetic nerve activity in 46 patients with essential hypertension. We performed 24-h Holter electrocardiography and ambulatory blood pressure (BP) monitoring simultaneously, and examined blood samples during the baseline, temocapril and amlodipine treatment periods. The ambulatory BP was lower in the amlodipine period than in the temocapril period. However, the number of VEB was significantly increased in the amlodipine period compared to that in the baseline period (11.9 vs. 7.4/day, p<0.05). In the temocapril period, the number of VEB was not significantly increased compared to that in the baseline period (8.6 vs. 7.4/day, p=0.30). Ambulatory heart rate (HR) was significantly increased in the amlodipine period compared to that in the baseline period (24-h HR: 70 vs. 66 bpm, p<0.001; daytime HR: 75 vs. 71 bpm, p<0.001; nocturnal HR: 60 vs. 58 bpm, p<0.05). Plasma norepinephrine (NE) also was significantly increased in the amlodipine period compared to that in the baseline period (457 vs. 369 pg/ml, p<0.001). However, when patients receiving amlodipine were divided into a high dose group (8.6 +/- 1.2 mg/day) and a low dose group (4.6 +/- 1.2 mg/day), increases in HR and plasma NE levels were found only in the high dose group. These results indicate that amlodipine is effective at lowering BP in older hypertensives, although it may increase VEB, especially when given at a high dose.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12135309     DOI: 10.1291/hypres.25.329

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  8 in total

1.  The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.

Authors:  Shizuka Aritomi; Hajime Koganei; Hirotaka Wagatsuma; Akira Mitsui; Tetsuya Ogawa; Kosaku Nitta; Tomoyuki Konda
Journal:  Heart Vessels       Date:  2010-10-05       Impact factor: 2.037

2.  Effects of azelnidipine and amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in hypertensive patients.

Authors:  Yumi Koike; Tetsuya Kawabe; Kanami Nishihara; Naomi Iwane; Takuzo Hano
Journal:  Hypertens Res       Date:  2016-07-21       Impact factor: 3.872

Review 3.  Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS.

Authors:  Corey B Toal; Peter A Meredith; Henry L Elliott
Journal:  Blood Press       Date:  2012-07-05       Impact factor: 2.835

4.  Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT).

Authors:  Kosuke Fukao; Kazunori Shimada; Makoto Hiki; Takashi Kiyanagi; Kuniaki Hirose; Atsumi Kume; Hiromichi Ohsaka; Rie Matsumori; Takeshi Kurata; Tetsuro Miyazaki; Hiroyuki Daida
Journal:  Cardiovasc Diabetol       Date:  2011-09-10       Impact factor: 9.951

5.  The effects of the L/N-type calcium channel blocker (cilnidipine) on sympathetic hyperactive morning hypertension: results from ACHIEVE-ONE.

Authors:  Kazuomi Kario; Shin-ichi Ando; Hidenori Kido; Jin Nariyama; Shin Takiuchi; Tetsuo Yagi; Toshiki Shimizu; Kazuo Eguchi; Minoru Ohno; Osamu Kinoshita; Takahisa Yamada
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-12-10       Impact factor: 3.738

6.  Inhibitory effects of azelnidipine tablets on morning hypertension.

Authors:  Kazuomi Kario; Yuki Sato; Masayuki Shirayama; Megumi Takahashi; Kazuhito Shiosakai; Katsutoshi Hiramatsu; Masahiro Komiya; Kazuyuki Shimada
Journal:  Drugs R D       Date:  2013-03

7.  Optimal timing for antihypertensive dosing: focus on valsartan.

Authors:  Ramón C Hermida; Diana E Ayala; Carlos Calvo
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

8.  L/T-type calcium channel blocker reduces non-Gaussianity of heart rate variability in chronic kidney disease patients under preceding treatment with ARB.

Authors:  Michio Fukuda; Yoshiaki Ogiyama; Ryo Sato; Toshiyuki Miura; Hidekatsu Fukuta; Masashi Mizuno; Ken Kiyono; Yoshiharu Yamamoto; Junichiro Hayano; Nobuyuki Ohte
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2016-04-18       Impact factor: 1.636

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.